Drug Trial Radar · NCT03175367
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Nov 10, 2017
Primary completion
May 22, 2020
Study completion Dec 14, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jun 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.
Conditions
- Hypercholesterolemia
Interventions
EvinacumabDrug
SC or IV administration
Matching placeboDrug
SC or IV administration
Background Lipid Modifying Therapy (LMT)Other
All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand)Time frame: Baseline and Week 16
Locations
95 sites in 20 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Office of Dr. John D Homan MD
Newport Beach, California
Preventive Cardiology Inc
Boca Raton, Florida
Care Research Center Inc
Doral, Florida
Florida Lipid Institute
Winter Park, Florida
St. Vincent Medical Group, Inc
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
EMMC Northeast Cardiology Assocites
Bangor, Maine
University of Maryland School of Medicine
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Heart Health Cardiology
Grand Rapids, Michigan
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Mt Sinai Ichan Medical Institute
New York, New York
Duke University Medical Center
Durham, North Carolina
Rowan Diagnostic Clinic
Salisbury, North Carolina
Capital Area Research, LLC
Camp Hill, Pennsylvania
The University Of Texas Health Science Center Houston
Houston, Texas
San Antonio Premiere Internal Medicine
San Antonio, Texas
Clear Clinical Research, LLC
Schertz, Texas
PharmaTex Research
Tyler, Texas
Wasatch Clinical Research
Salt Lake City, Utah
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Redcliffe Hospital
Redcliffe, Queensland, Australia
Medizinische Universitaetsklinik Graz
Graz, Austria
University Hospital Innsbruck - Tyrolean Hospital
Innsbruck, Tyrol, Austria
Robarts Research Institute
London, Ontario, Canada
SKDS Research Inc.
Newmarket, Ontario, Canada
Centre Etudes Cliniques Econogene-21
Chicoutimi, Quebec, Canada
Clinique des maladies lipidiques de Quebec
Québec, Quebec, Canada
University Hospital, Charles University
Hradec Králové, Czechia
Ikem Institut Klinicke A Experimentalni Mediciny
Prague, Czechia
CCR Prague, S.R.O
Prague, Prague 3, Czechia
Univerzita Karlova v Praze 1 Lekarska Fakulta
Karlov, Praha 2, Czechia
Sydvestjysk Sygehus
Esbjerg, Denmark
Regionshospitalet Herning
Herning, Denmark
Houpital Du Bocage
Dijon, France
Hopital G Et R Laennec
Nantes, Cedex, France
Edith Wolfson Medical Center
Holon, Israel
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.